Sept. 22, 2020—Qiagen has acquired the remaining 80.1 percent of NeuMoDx Molecular for $248 million in cash. The company purchased a 19.9 percent stake in NeuMoDx in 2018 along with the right to acquire the remaining NeuMoDx stake. As part of the 2018 deal, Qiagen has distributed the NeuMoDx 288 and NeuMoDx 96 platforms in Europe and other markets outside the United States.
“NeuMoDx’s automated molecular testing platforms offer a unique combination of speed, flexibility, throughput, and ease of use for molecular diagnostics assays, including laboratory-developed tests,” Thierry Bernard, CEO of Qiagen, said in a press statement. “NeuMoDx has built an unparalleled platform that has demonstrated superior value during the coronavirus pandemic. This will expand Qiagen’s portfolio of automated testing solutions and provide another driver for future growth.”
The NeuMoDx 288 and NeuMoDx 96 offer 13 CE-IVD-marked assays for infectious diseases, including a dedicated COVID-19 test, which has received FDA emergency use authorization. A multiplex test for influenza, respiratory syncytial virus, and SARS-CoV-2 is scheduled for launch in the fourth quarter of this year.